Bristol Myers Squibb (BMY)
(Real Time Quote from BATS)
$55.04 USD
+0.72 (1.33%)
Updated Nov 4, 2024 09:42 AM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
BMY 55.04 +0.72(1.33%)
Will BMY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
Company News for Nov 1, 2024
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
Initial Claims Lower-Than-Expected
Un-spooky Halloween: PCE, Jobless Claims Tame
Other News for BMY
Bristol-Myers Squibb's Cobenfy Shows Sustained Efficacy in Schizophrenia Treatment
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Jefferies Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
BMY Crosses Above Average Analyst Target
Bristol-Myers Squibb: Hold Rating Reflects Gradual Improvement and Strategic Caution